176 related articles for article (PubMed ID: 25036740)
1. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
4. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
5. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
Shafique S; Bibi N; Rashid S
J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
[TBL] [Abstract][Full Text] [Related]
6. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
Zhou Y; Yan F; Huo X; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
[TBL] [Abstract][Full Text] [Related]
10. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies.
Abdullah M; Guruprasad L
J Biomol Struct Dyn; 2019 Aug; 37(13):3410-3421. PubMed ID: 30146942
[TBL] [Abstract][Full Text] [Related]
12. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L
J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
16. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
17. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
18. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
19. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]